Patents by Inventor Elizabeth Abraham
Elizabeth Abraham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9157059Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: GrantFiled: October 9, 2014Date of Patent: October 13, 2015Assignee: Corning IncorporatedInventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Publication number: 20150024494Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: ApplicationFiled: October 9, 2014Publication date: January 22, 2015Inventors: SUPARNA SANYAL, DEEPA SAXENA, SUSAN XIUQI QIAN, ELIZABETH ABRAHAM
-
Patent number: 8916382Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: GrantFiled: May 19, 2014Date of Patent: December 23, 2014Assignee: Corning IncorporatedInventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Publication number: 20140287506Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: ApplicationFiled: May 19, 2014Publication date: September 25, 2014Applicant: Corning IncorporatedInventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Patent number: 8728818Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: GrantFiled: October 5, 2012Date of Patent: May 20, 2014Assignee: Corning IncorporatedInventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Publication number: 20130280803Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: ApplicationFiled: October 5, 2012Publication date: October 24, 2013Inventors: Supama Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Publication number: 20130185516Abstract: Systems and methods for prefetching cache lines into a cache coupled to a processor. A hardware prefetcher is configured to recognize a memory access instruction as an auto-increment-address (AIA) memory access instruction, infer a stride value from an increment field of the AIA instruction, and prefetch lines into the cache based on the stride value. Additionally or alternatively, the hardware prefetcher is configured to recognize that prefetched cache lines are part of a hardware loop, determine a maximum loop count of the hardware loop, and a remaining loop count as a difference between the maximum loop count and a number of loop iterations that have been completed, select a number of cache lines to prefetch, and truncate an actual number of cache lines to prefetch to be less than or equal to the remaining loop count, when the remaining loop count is less than the selected number of cache lines.Type: ApplicationFiled: January 16, 2012Publication date: July 18, 2013Applicant: QUALCOMM IncorporatedInventors: Peter G. Sassone, Suman Mamidi, Elizabeth Abraham, Suresh K. Venkumahanti, Lucian Codrescu
-
Publication number: 20130185515Abstract: Systems and methods for populating a cache using a hardware prefetcher are disclosed. A method for prefetching cache entries includes determining an initial stride value based on at least a first and second demand miss address in the cache, verifying the initial stride value based on a third demand miss address in the cache, prefetching a predetermined number of cache entries based on the verified initial stride value, determining an expected next miss address in the cache based on the verified initial stride value and addresses of the prefetched cache entries; and confirming the verified initial stride value based on comparing the expected next miss address to a next demand miss address in the cache. If the verified initial stride value is confirmed, additional cache entries are prefetched. If the verified initial stride value is not confirmed, further prefetching is stalled and an alternate stride value is determined.Type: ApplicationFiled: January 16, 2012Publication date: July 18, 2013Applicant: QUALCOMM INCORPORATEDInventors: Peter G. Sassone, Suman Mamidi, Elizabeth Abraham, Suresh K. Venkumahanti, Lucian Codrescu
-
Publication number: 20130051707Abstract: A lightweight, flexible, portable bag which can be filled with beach sand, rocks, dirt or other loose material is connected to the upper part of the pole of a beach umbrella by a long flexible cord. The lower portion of the cord is secured to the open end of the nylon bag. The upper end of the cord is connected to the upper end of the pole of the umbrella by a hook-and-loop type fastener strap which wraps around the umbrella pole. The lower end of the cord is fitted within a hem in the opening of the bag to form a drawstring for closure of the bag to retain the sand or loose material in the bag during use. One end of the cord is formed into a loop with the long end of the cord passing through the loop and connected to the umbrella pole. Tension on the cord during use will cinch the drawstring closed thus retaining the material within the bag. The weight of the bag connected to the upper part of the pole will stabilize the umbrella in light to moderate winds.Type: ApplicationFiled: August 30, 2011Publication date: February 28, 2013Inventors: Kathleen Pisano, Elizabeth Abraham
-
Patent number: 8288513Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: GrantFiled: July 24, 2009Date of Patent: October 16, 2012Assignee: Becton, Dickinson and CompanyInventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Publication number: 20100021998Abstract: In one aspect, there is provided a cell culturing substrate including: a cell culture surface having a film attached thereto, wherein the film includes one or more plasma polymerized monomers; and a coating on the film-coated surface, the coating deposited from a coating solution comprising one or more extracellular matrix proteins and an aqueous solvent, where the total extracellular matrix protein concentration in the coating solution is about 1 ng/mL to about 1 mg/mL.Type: ApplicationFiled: July 24, 2009Publication date: January 28, 2010Applicant: BECTON, DICKINSON AND COMPANYInventors: Suparna Sanyal, Deepa Saxena, Susan Xiuqi Qian, Elizabeth Abraham
-
Publication number: 20070128176Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: May 22, 2006Publication date: June 7, 2007Inventors: Joel Habener, Henryk Zulewski, Melissa Thomas, Elizabeth Abraham, Mario Vallejo, Colin Leech, Anna Nolan, Andreas Lechner
-
Publication number: 20070071730Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: April 24, 2006Publication date: March 29, 2007Inventors: Joel Habener, Henryk Zulewski, Elizabeth Abraham, Melissa Thomas, Mario Vallejo
-
Publication number: 20060062769Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: May 19, 2005Publication date: March 23, 2006Inventors: Joel Habener, Hendrik Zulewski, Elizabeth Abraham, Mario Vallejo, Denise Faustman, Melissa Thomas
-
Publication number: 20050244386Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: ApplicationFiled: November 9, 2004Publication date: November 3, 2005Inventors: Joel Habener, Henryk Zulewski, Elizabeth Abraham, Mario Vallejo, Denise Faustman, Melissa Thomas
-
Patent number: 6866843Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.Type: GrantFiled: December 6, 2000Date of Patent: March 15, 2005Assignee: Viacell, Inc.Inventors: Joel F. Habener, Henryk Zulewski, Elizabeth Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas